Leo Pharma is waving goodbye to its former CEO of its US operations, Christopher Posner. Posner has left the company to join the US-listed biotech business Cara Therapeutics, where he has sat on the board.
In a mail sent to MedWatch, Leo Pharma expresses its full understanding of Posner's choice to follow his new career opportunity.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.